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Abstract
Introduction: Breast cancer comprises clinically distinct subtypes, but most risk statistics consider breast cancer
only as a single entity. To estimate subtype-specific lifetime breast cancer risks, we took advantage of population-
based data for which information regarding tumor expression of estrogen receptor (ER), progesterone receptor (PR)
and HER2/neu (HER2) was newly available.
Methods: We included women whose breast cancer was diagnosed in the state of California from 2006 to 2007
and was reported to the National Cancer Institute’s Surveillance, Epidemiology and End Results Program (N =
40,936). We calculated absolute lifetime and age-specific probabilities (percent, 95% confidence interval) of
developing breast cancer subtypes defined by ER, PR, and HER2 status - luminal (ER and/or PR-positive, HER2-
negative), HER2-positive (ER and PR-positive or negative, HER2-positive), and triple-negative (ER-negative, PR-
negative, and HER2-negative) - separately for white, black, Hispanic, and Asian women.
Results: The luminal breast cancer subtype predominates across racial/ethnic groups, with lifetime risk lowest in
Hispanic women (4.60%, 4.41-4.80%) and highest in white women (8.10%, 7.94-8.20%). HER2-positive breast cancer
varies less by race (1.56-1.91%). Lifetime risk of triple-negative breast cancer is highest in black women (1.98%, 1.80-
2.17%), compared to 0.77% (0.67-0.88%) for Asians, 1.04% (0.96-1.13%) for Hispanics and 1.25% (1.20-1.30%) for
whites. Across racial/ethnic groups, nearly half of all luminal breast cancers occur after age 70.
Conclusions: These absolute risk estimates may inform health policy and resource planning across diverse
populations, and can help patients and physicians weigh the probabilities of developing specific breast cancer
subtypes against competing health risks.
Introduction
Breast cancers are biologically heterogeneous. Gene
expression profiling of breast tumor tissues has identi-
fied reliable patterns indicative of clinically distinct sub-
types [1-4]. At this time, the subtype classifications most
often used in clinical settings are based on the com-
monly measured tumor markers estrogen receptor (ER),
progesterone receptor (PR), and HER2/neu (HER2),
which offer imperfect but practical surrogates for geno-
mic profiling [5]. It is increasingly recognized that breast
cancer subtypes vary in occurrence (especially by race/
ethnicity) [5-8], in their detection by screening mammo-
graphy [9,10], and in their risk associations with other
factors [11-15]. Treatment options and prognosis also
depend on breast cancer subtype [9,16-18].
Despite accumulating evidence that breast cancer sub-
types should be considered separately, it is still routine
to present statistics that consider the disease as a single
entity. Perhaps most commonly cited is the 12% lifetime
probability statistic [19], prompting the widespread per-
ception that ‘one in eight’ US women will develop the
disease. This single estimate does not convey race-speci-
fic variation in breast cancer risks. Moreover, although
some groups are reported to have greater relative risk of
specific breast cancer subtypes, there are no data with
which to counsel patients about the absolute magnitude
of these risks in comparison with other threats to their
health; one clinically important example is the ER-, PR-,
and HER2-negative (triple-negative) breast cancer sub-
type among black women [5]. To provide estimates rele-
vant to patient care and health policy, we took
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patterns (collected in the large and diverse population of
California) to calculate absolute lifetime risks of devel-
oping a first primary breast cancer according to breast
cancer subtype and presented those calculations sepa-
rately for women of four racial/ethnic groups.
Materials and methods
Study population
The California Cancer Registry (CCR), a contributor to
the National Cancer Institute’s Surveillance, Epidemiol-
ogy and End Results (SEER) program, has ascertained all
cancers diagnosed in the state of California since 1988,
with estimated 99% completeness. In this analysis, we
included all invasive breast cancers (International Classi-
fication of Disease for Oncology, Third Edition [ICD-
O-3] sites 50.0 to 50.9; all histologies excluding sarco-
mas and lymphomas 9050 to 9055, 9140, and 9590 to
9989). The CCR has collected information on ER and PR
since 1990 and on HER2 since 1999. Before the year
2006, 29% of cases lacked HER2 data; subsequently,
HER2 data completeness increased to at least 85%, and
thus we limited our assessment to the 40,936 women
whose cancer was diagnosed between 1 January 2006 and
31 December 2007, comprising the most recent years for
which data are available from the CCR. Each marker is
reported as positive, negative, borderline, not tested, not
recorded, or unknown. ER and PR were evaluated by dex-
tran-coated charcoal assays or immunohistochemistry
(IHC), with positive defined as greater than or equal to
5% nuclear staining; HER2 was tested by IHC (with 0 and
1+ defined as negative, 2+ as borderline, and 3+ as posi-
tive) or fluorescence in situ hybridization (with fewer
than or equal to two gene copies defined as negative and
greater than two copies defined as positive) [20]. Tumor
size and stage at diagnosis, patient age at diagnosis, race,
and ethnicity were abstracted directly from the medical
record; in most cases (84%), race was derived from a
patient self-report [21]. We categorized race/ethnicity as
non-Hispanic (NH) white, NH black, Hispanic, and NH
Asian or Pacific Islander (hereafter referred to as white,
black, Hispanic, and Asian).
Categorization of breast cancer subtypes
We categorized breast cancer subtypes according to
tumor expression of ER, PR, and HER2; we designated
three subtype groupings, which are distinguished by
their differences in clinical management (consisting of
treatment with ER-, PR-, or HER2-targeted therapies)
and by their prognosis. Similarly to previous investiga-
tors [22], we defined a ‘luminal’ category as ER- or PR-
positive or both and HER2-negative (a category that
overlaps, but does not concord completely, with the
gene expression-based subtypes luminal A and luminal
B) [3,4]; other subtype categories were HER2-positive
(ER- and PR-positive or -negative and HER2-positive)
and triple-negative (ER-negative, PR-negative, and
HER2-negative) [5-8,17].
Statistical analysis
We used DevCan software (version 6.4.1), developed by
the National Cancer Institute, to compute absolute
probabilities that a specific breast cancer subtype will be
diagnosed and the associated 95% confidence intervals
(CIs) [23]. DevCan employs competing-risks methodol-
ogy to estimate age-dependent probabilities of cancer
occurrence and accounts for competing risks of death
(specifically, all non-breast cancer causes of death) and
is conditioned upon the patient’s never having had
breast cancer previously [24-27]. For each age group,
DevCan calculates the probabilities of two mutually
exclusive events: either developing the cancer of interest
or dying from other causes without ever having devel-
oped the cancer of interest. Consequently, cause-specific
mortality data are required to estimate incidence of the
cancer of interest. The DevCan program uses data on
cause-specific mortality for the US population; the data
are specific to age, sex, race, and calendar year and are
derived from the National Center for Health Statistics
(NCHS) of the Centers for Disease Control and Preven-
tion [23,28]. Since NCHS does not provide subtype-spe-
cific breast cancer mortality data, we used overall breast
cancer-specific mortality in place of breast cancer sub-
type-specific mortality and assumed that the difference
in these mortality rates would be small at the population
level. We limited our assessment to risks of developing a
first breast cancer [23] and did not consider second pri-
mary breast cancer (a rare event affecting only 4% of
breast cancer survivors) [29]. All analyses were con-
ducted in accordance with the Institutional Review
Board approval of the Cancer Prevention Institute of
California (protocol number 2001-043).
Results and Discussion
Study participants
From the cohort of 40,936 women whose breast cancer
was diagnosed in California in 2006-2007, we excluded
7,737 cases (18.9%) having any of the three markers ER,
PR, or HER2 coded as borderline, not tested, not
recorded, or unknown. This excluded group comprised
5,069 whites, 505 blacks, 1,262 Hispanics, and 901
Asians; there were no significant differences according
to race/ethnicity or age between the cases excluded for
missing ER, PR, or HER2 results and the included cases
that had ER, PR, and HER data available (results not
shown). We included a total of 33,199 women, for
whom data on ER, PR, and HER2 were available, in our
analyses. Table 1 presents demographic and clinical
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Race Breast cancers,
number
(percentage)
Age in years,
number
(percentage)
Stage,
number
(percentage)
Size, number
(percentage)
Luminal,
number
(percentage)
HER2-positive,
number
(percentage)
Triple-negative,
number
(percentage)
White 21,947 (66.1) <40: 786 (3.6) Local: 14,161
(64.5)
≤2 cm: 13,537
(61.7)
15,713 (71.6) 3,713 (16.9) 2,521 (11.5)
40-49: 3,442 (15.7) Reg/Dist: 7,737
(35.2)
>2 cm, ≤5 cm:
6,386 (29.1)
50-59: 5,335 (24.3) Unstaged: 49
(0.2)
>5 cm: 1,475
(6.7)
60-69: 5,468 (24.9) Not available:
549 (2.5)
≥70: 6,916 (31.5)
Black 2,071 (6.2) <40: 137 (6.6) Local: 1,128
(54.5)
≤2 cm: 1,007
(48.6)
1,098 (53.0) 464 (22.4) 509 (24.6)
40-49: 474 (22.9) Reg/Dist: 931
(45.0)
> 2 cm, ≤5
cm: 737 (35.6)
50-59: 553 (26.7) Unstaged: 12
(0.6)
> 5 cm: 250
(12.1)
60-69: 461 (22.3) Not available:
77 (3.7)
≥70: 446 (21.5)
Hispanic 5,523 (16.6) <40: 582 (10.5) Local: 3,013
(54.6)
≤2 cm: 2,788
(50.5)
3,275 (59.3) 1,328 (24.0) 920 (16.7)
40-49: 1,419 (25.7) Reg/Dist: 2,476
(44.8)
>2 cm, ≤5 cm:
1,993 (36.1)
50-59: 1,414 (25.6) Unstaged: 34
(0.6)
>5 cm: 562
(10.2)
60-69: 1,092 (19.8) Not available:
180 (3.3)
≥70: 1,016 (18.4)
Asian 3,658 (11.0) <40: 298 (8.1) Local: 2,258
(61.7)
≤2 cm: 2,069
(56.6)
2,296 (62.8) 994 (27.2) 368 (10.0)
40-49: 910 (24.9) Reg/Dist: 1,385
(37.9)
>2 cm, ≤5 cm:
1,212 (33.1)
50-59: 1,057 (28.9) Unstaged: 15
(0.4)
>5 cm: 301
(8.2)
60-69: 712 (19.5) Not available:
76 (2.1)
≥70: 681 (18.6)
All
races
a
33,199 (100) <40: 1,803 (5.4) Local: 20,560
(61.9)
≤2 cm: 19,401
(58.4)
22,382 (67.4) 6,499 (19.6) 4,318 (13)
40-49: 6,245 (18.8) Reg/Dist:
12,529 (37.7)
>2 cm, ≤5 cm:
10,328 (31.1)
50-59: 8,359 (25.2) Unstaged: 110
(0.3)
>5 cm: 2,588
(7.8)
60-69: 7,733 (23.3) Not available:
882 (2.7)
≥70: 9,059 (27.3)
Chi-square test for subtype by race: P < 0.0001
Data include age, race/ethnicity, stage (local, regional or distant [Reg/Dist], or unstaged), tumor size, and subtype: luminal (estrogen receptor [ER]- or
progesterone receptor [PR]-positive or both and HER2/neu [HER2]-negative), HER2-positive (ER- and PR-positive or -negative and HER2-positive), and triple-
negative (ER-negative, PR-negative, and HER2-negative).
aExcludes 7,737 cases (5,069 whites, 505 blacks, 1,262 Hispanics, and 901 Asians) for whom ER, PR, or
HER2 were untested, borderline, missing, or unknown.
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the CCR. Among breast cancer cases, 66.1% were white,
6.2% black, 16.6% Hispanic, and 11% Asian. Compared
with other racial groups, white patients had a higher
proportion of tumors that were luminal (71.6% versus
53% to 62.8%), that were diagnosed in local stage (64.5%
versus 54.5% to 61.7%), and that were diagnosed at a
size of 2 cm or less (61.7% versus 48.6% to 58.4%).
Black women had the highest proportion of tumors that
were triple-negative (24.6% versus 10% to 16.7%). A chi-
square test of breast cancer subtypes by race yielded a
P value of less than 0.0001, indicating a statistically sig-
nificant difference in subtype distribution between racial
groups.
Lifetime risks by racial/ethnic group
Table 2 presents absolute lifetime risks of developing
specific breast cancer subtypes for white, black, Hispa-
nic, and Asian women. All racial/ethnic groups have a
higher lifetime risk of developing luminal breast cancer
than any other subtype, but this luminal breast cancer
risk varies significantly by race/ethnicity and ranges
from 4.60% (95% CI 4.40% to 4.81%) for Hispanics to
8.10% (95% CI 7.94% to 8.20%) for whites. Although the
95% CIs around risks for HER2-positive breast cancer
do not overlap between most racial/ethnic groups (for
example, Hispanics 1.56%, 95% CI 1.46% to 1.68% and
Asians 1.91%, 95% CI 1.78% to 2.07%), the risk differ-
ences are smaller in magnitude than for the luminal
subtype. For triple-negative breast cancer, blacks have
the highest lifetime risk at 1.98% (95% CI 1.80% to
2.17%), which is significantly greater than that of Asian
(0.77%, 95% CI 0.67% to 0.88%), Hispanic (1.04%, 95%
CI 0.96% to 1.13%), and white (1.25%, 95% CI 1.20% to
1.30%) women. For all races and all subtypes combined,
overall absolute risk is 12.3% (95% CI 12.2% to 12.4%),
which is consistent with 1 in 8 women developing breast
cancer in her lifetime. Figure 1 presents race-specific
incidence curves for each subtype.
Absolute risks by age and racial/ethnic group
Table 3 presents age-specific risks for breast cancer sub-
types for women who are unaffected by cancer at age 40.
Between the ages of 40 and 49, white women have 0.87%
(95% CI 0.84% to 0.90%) probability of developing lumi-
nal breast cancer, 0.27% (95% CI 0.25% to 0.29%) prob-
ability of developing HER2-positive breast cancer, and
0.17% (95% CI 0.16% to 0.19%) probability of developing
triple-negative breast cancer; for blacks, corresponding
probabilities are 0.59% (95% CI 0.52% to 0.66%), 0.31%
(95% CI 0.26% to 0.37%), and 0.34% (95% CI 0.29% to
0.40%). For all races, nearly half the lifetime probability
of developing luminal breast cancer occurs after age 70,
whereas triple-negative breast cancer and HER2-positive
breast cancer subtypes have an earlier age distribution, as
shown in Figure 2. The Supplemental table (Additional
file 1) presents age-specific risks in 10-, 20-, and 30-year
intervals in addition to lifetime risks for women ages 20
to 80 by race/ethnicity and by breast cancer subtype.
Conclusions
We present lifetime and age-specific probabilities of devel-
oping luminal (ER- or PR-positive or both and HER2-
negative), HER2-positive (ER- and PR-positive or -negative
and HER2-positive), and triple-negative (ER-, PR-, and
HER2-negative) subtypes of breast cancer for women from
four racial/ethnic groups and use the most recently avail-
able data from the large and diverse population of
California. These estimates refine the frequently cited ‘one
in eight’ statistic [12], which fails to capture the substantial
differences in epidemiology and prognosis among breast
cancer subtypes [6-9,16,17]. Most importantly, these esti-
mates facilitate clinically relevant discussion between
patients and physicians. For women considering preven-
tion strategies such as prophylactic tamoxifen or raloxi-
fene, which reduce the incidence of only certain subtypes
of breast cancer [30,31], or screening methods such as
magnetic resonance imaging (MRI), which may contribute
more to the detection of triple-negative than luminal
Table 2 Absolute lifetime risk
a of developing breast cancer by subtype
b and race/ethnicity
c
White Black Hispanic Asian All races
Breast cancer subtype Percentage (95% CI) Percentage (95% CI) Percentage (95% CI) Percentage (95% CI) Percentage (95% CI)
Luminal
b, d 8.10 (7.94, 8.20) 4.70 (4.41, 5.02) 4.60 (4.41, 4.80) 5.06 (4.81, 5.34) 6.79 (6.69, 6.88)
HER2-positive
b, d 1.82 (1.76, 1.88) 1.81 (1.63, 2.00) 1.56 (1.46, 1.68) 1.91 (1.78, 2.07) 1.78 (1.73, 1.83)
Triple-negative
b, d 1.25 (1.20, 1.30) 1.98 (1.80, 2.17) 1.04 (0.96, 1.13) 0.77 (0.67, 0.88) 1.20 (1.16, 1.24)
Missing
e 2.68 (2.60, 2.76) 2.32 (2.11, 2.56) 1.81 (1.68, 1.95) 2.23 (2.04, 2.44) 2.44 (2.38, 2.50)
All subtypes 13.8 (13.6, 14.0) 10.8 (10.4, 11.3) 9.01 (8.74, 9.29) 9.98 (9.61, 10.4) 12.3 (12.2, 12.4)
aLifetime risk is conditioned on never having had breast cancer previously.
bSubtypes were defined by expression of estrogen receptor (ER), progesterone
receptor (PR), and Her2/neu (HER2) as follows: luminal (ER- or PR-positive or both and HER2-negative), HER2-positive (ER- and PR-positive or -negative and HER2-
positive), and triple-negative (ER-negative, PR-negative, and HER2-negative).
cRacial/ethnic categories are mutually exclusive and include white (non-Hispanic
white), black (non-Hispanic black), Hispanic, and Asian (non-Hispanic Asian or Pacific Islander).
dExcludes 7,737 cases (5,069 whites, 505 blacks, 1,262 Hispanics,
and 901 Asians) for whom ER, PR, and/or HER2 were not tested or for whom results were borderline, missing, or unknown; these cases are included in the ‘All
subtypes’ category.
eIncludes 7,737 cases (5,069 whites, 505 blacks, 1,262 Hispanics, and 901 Asians) for whom ER, PR, and/or HER2 were not tested or for whom
results were borderline, missing or unknown. CI, confidence interval.
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managing breast cancer risk. A woman at low risk for a
specific subtype might choose to forego particular inter-
ventions and their side effects (for example, stroke and
uterine cancer from tamoxifen or false-positive biopsies
from screening mammogram or MRI) [30,32], depending
on the relative importance of such side effects and her
competing health risks.
We present statistics separately for women in four
major racial/ethnic groupings because lifetime risks for
breast cancer as a whole vary substantially by these
groups. Most notable were the significantly increased
risks of luminal breast cancer among whites and of tri-
ple-negative breast cancer among black women. Our
findings are consistent with studies reporting greater
relative risks of triple-negative breast cancer among
black women [5,7,8,33] and strengthen the rationale for
investigating genetic, reproductive, and lifestyle factors
that may mediate this racial difference, such as age at
menarche, family cancer history, breastfeeding, and
abdominal adiposity [34,35]. In all groups, the luminal
subtype was the most common one. This universal
predominance of luminal (ER- or PR-positive or both
and HER2-negative) breast cancer, regardless of race,
may be reassuring since this subtype has the best survi-
val [5,17], can be targeted by existing chemoprevention
agents [30,31], and may be most readily detectable by
screening mammography [9,10,36,37]. Although the dis-
proportionately increased risk among black women of
poor-prognosis triple-negative breast cancer warrants
further study and targeted interventions, black women
may be reassured to learn that they also have a high
probability of avoiding this disease over their lifetimes.
It is essential to differentiate risks according to a
woman’s current age. A prior analysis using SEER data
characterized qualitative patterns of breast cancer inci-
dence according to ER status and reported an age-related
crossover between black and white women [38]. We found
that, for all races and for all subtypes, absolute breast can-
cer risks were low between ages 40 and 49 years: less than
1% per subtype and less than 2% for all subtypes com-
bined. For women between ages 50 and 59, risks of each
subtype increased substantially, and the greatest increase
was for luminal breast cancers in white women. Nearly
Figure 1 Age-specific incidence of breast cancer. Incidence is expressed as rates per 100,000 by age (in years) for subtypes - luminal (ER- or
PR-positive or both and HER2-negative), HER2-positive (ER- and PR-positive or -negative and HER2-positive), and triple-negative (ER-negative, PR-
negative, and HER2-negative) - and for racial/ethnic groups: (a) whites, (b) blacks, (c) Hispanics, and (d) Asians. ER, estrogen receptor; HER2,
Her2/neu; PR, progesterone receptor.
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a to develop breast cancer in specific age intervals for cancer-free 40-year-old women by
subtype
b and race/ethnicity
c
Luminal
b, d HER2-positive
b, d Triple-negative
b, d All subtypes
Race/Ethnicity Percentage (95% CI) Percentage (95% CI) Percentage (95% CI) Percentage (95% CI)
White, age 40
To age 50 0.87 (0.84, 0.90) 0.27 (0.25, 0.29) 0.17 (0.16, 0.19) 1.57 (1.52, 1.61)
To age 70 4.54 (4.45, 4.63) 1.13 (1.09, 1.18) 0.76 (0.72, 0.79) 7.78 (7.67, 7.90)
To end of life 8.00 (7.87, 8.14) 1.74 (1.68, 1.80) 1.19 (1.14, 1.24) 13.6 (13.5, 13.8)
Black, age 40
To age 50 0.59 (0.52, 0.66) 0.31 (0.26, 0.37) 0.34 (0.29, 0.40) 1.51 (1.40, 1.63)
To age 70 2.83 (2.63, 3.03) 1.19 (1.07, 1.33) 1.31 (1.18, 1.45) 6.49 (6.02, 6.80)
To end of life 4.55 (4.35, 4.76) 1.73 (1.55, 1.92) 1.91 (1.73, 2.11) 10.7 (10.3, 11.2)
Hispanic, age 40
To age 50 0.49 (0.46, 0.52) 0.23 (0.21, 0.25) 0.16 (0.14, 0.17) 1.07 (1.03, 1.12)
To age 70 2.49 (2.38, 2.59) 0.94 (0.88, 1.01) 0.65 (0.60, 0.71) 4.99 (4.85, 5.14)
To end of life 4.79 (4.59, 5.00) 1.50 (1.39, 1.61) 0.98 (0.90, 1.07) 8.83 (8.56, 9.11)
Asian, age 40
To age 50 0.71 (0.66, 0.77) 0.34 (0.30, 0.38) 0.10 (0.08, 0.12) 1.41 (1.34, 1.49)
To age 70 2.81 (2.68, 2.95) 1.28 (1.19, 1.37) 0.45 (0.40, 0.51) 5.67 (5.47, 5.87)
To end of life 4.92 (4.66, 5.20) 1.70 (1.66, 1.97) 0.72 (0.63, 0.84) 9.68 (9.31, 10.1)
All races, age 40
To age 50 0.72 (0.70, 0.74) 0.27 (0.26, 0.28) 0.17 (0.16, 0.18) 1.41 (1.38, 1.44)
To age 70 3.72 (3.66, 3.78) 1.12 (1.08, 1.15) 0.73 (0.70, 0.76) 6.83 (6.75, 6.91)
To end of life 6.74 (6.64, 6.84) 1.70 (1.66, 1.75) 1.14 (1.10, 1.18) 12.1 (12.0, 12.3)
aRisk is conditioned on never having had breast cancer previously.
bSubtypes were defined by expression of estrogen receptor (ER), progesterone receptor (PR),
and Her2/neu (HER2): luminal (ER- or PR-positive or both and HER2-negative), HER2-positive (ER- and PR-positive or -negative and HER2-positive), and triple-
negative (ER-negative, PR-negative, and HER2-negative).
cRacial/ethnic categories are mutually exclusive and include white (non-Hispanic [NH]), black (NH),
Hispanic, and Asian (NH, includes Pacific Islander).
dExcludes 7,737 cases (5,069 whites, 505 blacks, 1,262 Hispanics, and 901 Asians) for whom ER, PR, and/or
HER2 were not tested or for whom results were borderline, missing, or unknown; these cases are included in the ‘All subtypes’ category. CI, confidence interval.
Figure 2 Distribution of breast cancer subtypes by age. Distribution is expressed as a percentage, and age is expressed in years. Subtypes
are defined as (a) luminal (ER- or PR-positive or both and HER2-negative), (b) HER2-positive (ER- and PR-positive or -negative and HER2-positive),
and (c) triple-negative (ER-negative, PR-negative, and HER2-negative). ER, estrogen receptor; HER2, Her2/neu; PR, progesterone receptor.
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nant subtype for all racial/ethnic groups, occurred at or
after age 70. These findings are important to the ongoing
critical examination of mammographic screening guide-
lines [32,36,39] and may warrant extending recommenda-
tions for mammographic screening beyond the current
upper limit of 69 years of age [32].
Our analyses have certain limitations, which should be
considered in interpreting our results. Given the Dev-
Can program’s competing-risks methodology, cause-
specific mortality is required to calculate incidence of
the cancer in question [23,25]; we used overall US
breast cancer mortality rates to calculate subtype-
specific incidence [28] because subtype-specific mortality
rates are not available. However, since overall breast
cancer mortality is low at the population level, this is
unlikely to affect our risk estimates substantially. Racial
misclassification might present another potential source
of bias, but given that prior studies of the CCR found
that race data derive from patient self-report in more
than 80% of cases [21], it seems improbable that a large
proportion were incorrectly classified. We excluded
7,737 cases (18.9%) from analysis because of missing ER,
PR, or HER2 information; since there were no major dif-
ferences in race or age distribution between the
excluded and included cases, the lack of information on
these cases seems unlikely to have biased our findings.
Although defining subtypes by ER, PR, and HER2
expression does not entirely approximate results of
genomic profiling, this classification offers a practical
substitute that is increasingly well characterized in pub-
lished literature [5,7-9,40-42] and that guides breast can-
cer treatment [43].
This study reports average lifetime risks at the popula-
tion level; it does not address the urgent need for more
accurate risk stratification of individual patients or the
limitations of current breast cancer risk prediction mod-
els [44]. Genetic mutations such as BRCA1 convey dra-
matically increased risks of triple-negative breast cancer
[45,46], and the results of genome-wide association stu-
dies may eventually guide even more personalized risk
prediction [47,48]. Our estimates may inform health pol-
icy and resource planning across diverse populations
and may help patients and clinicians to weigh the aver-
age probabilities of developing specific breast cancer
subtypes against other competing health risks.
Additional material
Additional File 1: Supplemental table. Absolute risk (%) to develop
breast cancer in specific age intervals, for cancer-free women by subtype
and race/ethnicity.
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